These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 20578842)
1. Stability of 3'-deoxy-3'-[18F]fluorothymidine standardized uptake values in head and neck cancer over time. Boles Ponto LL; Menda Y; Dornfeld K; Tewson TJ; Watkins GL; Sunderland J; Graham MM; Buatti J Cancer Biother Radiopharm; 2010 Jun; 25(3):361-3. PubMed ID: 20578842 [TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. Menda Y; Boles Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Schultz MK; Sunderland JJ; Graham MM; Buatti JM J Nucl Med; 2009 Jul; 50(7):1028-35. PubMed ID: 19525472 [TBL] [Abstract][Full Text] [Related]
3. Investigation of the pharmacokinetics of 3'-deoxy-3'-[18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Menda Y; Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Gupta AK; Anderson C; McGuire S; Schultz MK; Sunderland JJ; Graham MM; Buatti JM Nucl Med Biol; 2010 May; 37(4):433-8. PubMed ID: 20447554 [TBL] [Abstract][Full Text] [Related]
4. Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. Trigonis I; Koh PK; Taylor B; Tamal M; Ryder D; Earl M; Anton-Rodriguez J; Haslett K; Young H; Faivre-Finn C; Blackhall F; Jackson A; Asselin MC Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):682-93. PubMed ID: 24504503 [TBL] [Abstract][Full Text] [Related]
5. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy. Hoshikawa H; Mori T; Kishino T; Yamamoto Y; Inamoto R; Akiyama K; Mori N; Nishiyama Y Ann Nucl Med; 2013 May; 27(4):363-70. PubMed ID: 23378102 [TBL] [Abstract][Full Text] [Related]
6. 3'-deoxy-3'-[¹⁸F]fluorothymidine PET quantification of bone marrow response to radiation dose. McGuire SM; Menda Y; Boles Ponto LL; Gross B; Buatti J; Bayouth JE Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):888-93. PubMed ID: 21300484 [TBL] [Abstract][Full Text] [Related]
7. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960 [TBL] [Abstract][Full Text] [Related]
8. [18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Contractor KB; Kenny LM; Stebbing J; Rosso L; Ahmad R; Jacob J; Challapalli A; Turkheimer F; Al-Nahhas A; Sharma R; Coombes RC; Aboagye EO Clin Cancer Res; 2011 Dec; 17(24):7664-72. PubMed ID: 22028493 [TBL] [Abstract][Full Text] [Related]
9. Predictive value of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma. Inubushi M; Saga T; Koizumi M; Takagi R; Hasegawa A; Koto M; Wakatuki M; Morikawa T; Yoshikawa K; Tanimoto K; Fukumura T; Yamada S; Kamada T Ann Nucl Med; 2013 Jan; 27(1):1-10. PubMed ID: 22914968 [TBL] [Abstract][Full Text] [Related]
10. Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET/CT for short-term outcome with head and neck cancers. Hoshikawa H; Yamamoto Y; Mori T; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y Ann Nucl Med; 2014 Dec; 28(10):1020-6. PubMed ID: 25179522 [TBL] [Abstract][Full Text] [Related]
11. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity. Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329 [TBL] [Abstract][Full Text] [Related]
12. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial. Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593 [TBL] [Abstract][Full Text] [Related]
13. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Pio BS; Park CK; Pietras R; Hsueh WA; Satyamurthy N; Pegram MD; Czernin J; Phelps ME; Silverman DH Mol Imaging Biol; 2006; 8(1):36-42. PubMed ID: 16362149 [TBL] [Abstract][Full Text] [Related]
14. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer? Schaefferkoetter JD; Carlson ER; Heidel RE J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746 [TBL] [Abstract][Full Text] [Related]
15. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. Schiepers C; Dahlbom M; Chen W; Cloughesy T; Czernin J; Phelps ME; Huang SC J Nucl Med; 2010 May; 51(5):720-7. PubMed ID: 20395318 [TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET. Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872 [TBL] [Abstract][Full Text] [Related]
18. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411 [TBL] [Abstract][Full Text] [Related]
19. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487 [TBL] [Abstract][Full Text] [Related]